HLS Therapeutics (HLS) News Today C$3.35 +0.21 (+6.69%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 25 at 7:05 AM | sg.finance.yahoo.comFTSE 100 LIVE: European stocks slump after Wall Street suffers worst sell-off in over a yearJuly 25 at 7:05 AM | ca.finance.yahoo.comHLS Therapeutics to Host Q2 Fiscal 2024 Financial Results Conference CallJuly 24 at 7:17 PM | marketbeat.comHLS Therapeutics (TSE:HLS) Reaches New 12-Month Low at $3.07HLS Therapeutics (TSE:HLS) Reaches New 1-Year Low at $3.07July 19, 2024 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc flat on Wednesday (HLS)July 2, 2024 | marketbeat.comHLS Therapeutics (TSE:HLS) Hits New 12-Month Low at $3.25HLS Therapeutics (TSE:HLS) Hits New 52-Week Low at $3.25June 17, 2024 | marketbeat.comHLS Therapeutics (TSE:HLS) Sets New 52-Week Low at $3.26HLS Therapeutics (TSE:HLS) Reaches New 1-Year Low at $3.26May 28, 2024 | finance.yahoo.comNew Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine TreatmentMay 10, 2024 | marketbeat.comRaymond James Lowers HLS Therapeutics (TSE:HLS) Price Target to C$4.00Raymond James reduced their price objective on shares of HLS Therapeutics from C$5.00 to C$4.00 in a research note on Friday.May 9, 2024 | morningstar.comHLS Therapeutics Inc HLSMay 9, 2024 | finance.yahoo.comHLS Therapeutics Announces Q1 2024 Financial ResultsApril 9, 2024 | finance.yahoo.comHLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 8, 2024 | finance.yahoo.comNew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsMarch 18, 2024 | marketbeat.comHLS Therapeutics (TSE:HLS) PT Lowered to C$5.00 at Raymond JamesRaymond James lowered their price objective on HLS Therapeutics from C$6.50 to C$5.00 in a report on Monday.March 17, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their HLS Therapeutics Inc. (TSE:HLS) Price Target To CA$6.57March 15, 2024 | marketbeat.comStifel Nicolaus Trims HLS Therapeutics (TSE:HLS) Target Price to C$4.15Stifel Nicolaus cut their price objective on HLS Therapeutics from C$4.35 to C$4.15 in a research report on Friday.March 14, 2024 | finance.yahoo.comHLS Therapeutics Inc. (TSE:HLS) stock most popular amongst retail investors who own 40%, while hedge funds hold 39%March 14, 2024 | finance.yahoo.comHLS Therapeutics Announces Fiscal 2023 Financial ResultsMarch 13, 2024 | markets.businessinsider.comHLS Therapeutics earnings: here's what to expectFebruary 21, 2024 | finance.yahoo.comSeveral Insiders Invested In HLS Therapeutics Flagging Positive NewsFebruary 9, 2024 | marketbeat.comHLS Therapeutics Inc. (TSE:HLS) Expected to Post FY2023 Earnings of ($0.93) Per ShareHLS Therapeutics Inc. (TSE:HLS - Free Report) - Clarus Securities issued their FY2023 earnings per share (EPS) estimates for shares of HLS Therapeutics in a report issued on Tuesday, February 6th. Clarus Securities analyst G. Ulybyshev expects that the company will post earnings of ($0.93) per shFebruary 9, 2024 | marketbeat.comHLS Therapeutics' (HLS) "Buy" Rating Reiterated at Clarus SecuritiesClarus Securities reaffirmed a "buy" rating on shares of HLS Therapeutics in a research note on Tuesday.February 6, 2024 | ca.finance.yahoo.comStocks in play: HLS Therapeutics Inc.February 6, 2024 | finance.yahoo.comHLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug PlanDecember 20, 2023 | msn.comPharma breakthroughs: 10 novel drug approvals that made headlines in 2023December 18, 2023 | marketwatch.comHLS Therapeutics CFO Tim Hendrickson to Step DownDecember 18, 2023 | msn.comHLS Therapeutics appoints John Hanna as interim CFODecember 18, 2023 | finance.yahoo.comHLS Therapeutics Announces CFO DepartureDecember 11, 2023 | msn.com2 Top Pharmaceutical Stocks to Buy on the TSX TodayNovember 15, 2023 | finance.yahoo.comSome HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Year's EstimatesNovember 14, 2023 | finance.yahoo.comNew REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at BaselineNovember 9, 2023 | marketwatch.comHLS Therapeutics Plans to Buyback Up to 5% of Its SharesNovember 9, 2023 | finance.yahoo.comHLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer BidNovember 9, 2023 | markets.businessinsider.comHLS Therapeutics earnings preview: what Wall Street is expectingOctober 2, 2023 | finance.yahoo.comEmergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of DirectorsSeptember 7, 2023 | finance.yahoo.comPositive Signs As Multiple Insiders Buy HLS Therapeutics StockAugust 26, 2023 | seekingalpha.comHLTRF HLS Therapeutics Inc.August 23, 2023 | theglobeandmail.comHLS Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (HLS)August 13, 2023 | markets.businessinsider.comBloom Burton Remains a Buy on HLS Therapeutics Inc (HLS)August 11, 2023 | marketbeat.comHLS Therapeutics (TSE:HLS) Issues Earnings ResultsHLS Therapeutics (TSE:HLS - Get Free Report) issued its quarterly earnings data on Thursday. The company reported C($0.39) EPS for the quarter, missing analysts' consensus estimates of C($0.17) by C($0.22). HLS Therapeutics had a negative return on equity of 18.55% and a negative net margin of 41.79%. During the same quarter in the prior year, the business posted ($0.36) EPS.August 11, 2023 | marketbeat.comHLS Therapeutics (TSE:HLS) Price Target Cut to C$15.00Stifel Nicolaus reduced their price objective on shares of HLS Therapeutics from C$18.00 to C$15.00 in a research report on Friday.August 3, 2023 | finance.yahoo.comHLS Therapeutics to Host Q2 Fiscal 2023 Financial Results Conference CallAugust 3, 2023 | msn.comHLS Therapeutics (HLTRF) Price Target Decreased by 12.21% to 11.36July 28, 2023 | markets.businessinsider.comHLS Therapeutics Inc (HLS) Gets a Hold Rating from Raymond JamesJuly 28, 2023 | marketbeat.comRaymond James Trims HLS Therapeutics (TSE:HLS) Target Price to C$9.00Raymond James cut their price target on HLS Therapeutics from C$10.00 to C$9.00 and set a "market perform" rating for the company in a report on Friday.July 28, 2023 | finance.yahoo.comWith 38% ownership, HLS Therapeutics Inc. (TSE:HLS) has piqued the interest of hedge funds investorsJuly 10, 2023 | markets.businessinsider.comStifel Nicolaus Remains a Buy on HLS Therapeutics Inc (HLS)July 6, 2023 | fool.comHls Therapeutics (TSX: HLS)July 1, 2023 | finance.yahoo.comAthyrium Capital Announces Sale of Shares of HLS TherapeuticsJune 22, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on HLS Therapeutics Inc (HLS)June 22, 2023 | marketwatch.comHLS Therapeutics Names John Welborn Chairman, Adds Polar Asset Management Candidate to Board Get HLS Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter. Email Address We just added a $300 account credit to your MarketBeat subscription (Ad)MarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days. Start Your Risk-Free Trial Here HLS Media Mentions By Week HLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HLS News Sentiment▼-0.610.62▲Average Medical News Sentiment HLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HLS Articles This Week▼30▲HLS Articles Average Week Get HLS Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Organigram News Today Cardiol Therapeutics News Today Cipher Pharmaceuticals News Today BioSyent News Today Charlotte's Web News Today MediPharm Labs News Today Decibel Cannabis News Today Crescita Therapeutics News Today Willow Biosciences News Today Medicure News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:HLS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HLS Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HLS Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HLS Stock Alerts